Is Ozempic a Boon or Bane for Thai Patients with Eating Disorders?
The rise of GLP-1 drugs like Ozempic, known scientifically as semaglutide, has sparked global interest due to their impressive ability to assist in weight loss. However, recent discussions raise alarms regarding their impact on patients with eating disorders. This concern is especially poignant in the context of Thai society, where body image issues and dietary habits are influenced by unique cultural and social dynamics.
Ozempic acts by mimicking a natural hormone that regulates insulin and slows stomach emptying, enhancing the feeling of fullness. It is celebrated as a “miracle drug” for weight management, yet its appetite-suppressant properties may pose risks to individuals prone to eating disorders like anorexia and bulimia. According to Dr. Kimberly Dennis, a U.S. psychiatrist specializing in eating disorders, such medications could act as “rocket fuel” for these disorders, potentially exacerbating unhealthy eating behaviors in vulnerable patients. This sentiment is echoed by Pamela Keel, a psychologist with expertise in eating disorders, who warns against prescribing these drugs to malnourished individuals.